Comparing the current results to its competitors, Iovance Biotherapeutics Inc reported Revenue increase in the 1 quarter 2026 by 44.82 % year on year. The sales growth was above Iovance Biotherapeutics Inc 's competitors' average revenue growth of 4.77 %, achieved in the same quarter.
Iovance Biotherapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries alongside numerous entities with greater resources and experience. Competitors include large and specialty pharmaceutical and biotechnology companies, early-stage companies, universities, and research institutions developing cancer therapies, immuno-oncology treatments, and novel IL-2 products. These competitors have developed, approved, and commercialized several therapeutic products or are pursuing regulatory approval in the U.S. and internationally. They may obtain regulatory approvals more quickly, potentially establishing strong market positions ahead of the company. Competition also occurs in recruiting personnel, establishing clinical trial sites, and acquiring relevant technologies.
Strong sales growth of 44.82 % in Overall company contributed to Iovance Biotherapeutics inc increase in total revenue by 44.82 % Iovance Biotherapeutics inc improved its market share in this segment, to approximately 0.15 %.
May 21, 2025
A Balanced Perspective on the Legal Proceedings Facing Iovance Biotherapeutics and Its Market Position for CSIMarket.com Context and Legal Developments Iovance Biotherapeutics, Inc. a biotechnology company focused on the development of novel cancer immunotherapies, has been thrust into the spotlight due to legal challenges. On May 21, 2025, Rosen Law Firm, a prominent global investor rights law firm, announced the filing of a class action lawsuit against the company on behalf of investors who purchased Iovance securities between May 9, 2024, and May 8, 2025. This lawsuit alleges violations of federal securities laws, and investors have until July 14, 2025, to petition the court to serve as lead plaintiff i...
February 16, 2024
Iovance s AMTAGVI (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced MelanomaIn a groundbreaking development, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Iovance Biotherapeutics AMTAGVI (lifileucel), making it the first FDA-approved T cell therapy for a solid tumor cancer. Specifically designed as a treatment option for advanced melanoma patients who have undergone anti-PD-1 and targeted therapy, this approval marks a significant leap forward in the fight against this devastating disease.Melanoma, the most severe type of skin cancer, affects thousands of individuals each year. Despite advancements in other forms of cancer treatment, patients with advanced me...
December 27, 2023
The arena of cancer research and treatment is continually evolving with the tireless efforts and innovation of biotechnology firms globally. One such entity leading the charge is Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). The biotechnology company, rooted firmly in the development and deployment of pioneering polyclonal tumor-infiltrating lymphocyte (TIL) therapies for cancer patients, has lately revealed an update regarding their clinical trials for LN-145 TIL therapy.Located in San Carlos, California, Iovance Biotherapeutics has been diligently researching and conducting clinical trials on LN-145, a promising TIL therapy specifically targeted at non-small cell lung cancer (NSCLC) patients. The company r...
Publicly Traded Peers of Iovance Biotherapeutics inc
Apogee Therapeutics Inc Share Performance
+71.60%
This Quarter
Apogee Therapeutics Inc
Profile
Apogee Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions. Their business model revolves around conducting extensive research to identify potential drug candidates, and then advancing them through preclinical and clinical trials to secure regulatory approvals. By licensing or partnering with larger pharmaceutical companies, Apogee Therapeutics aims to bring these drugs to market and improve patient outcomes.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.
Valneva is a biotech company that specializes in the development and commercialization of vaccines. Their business model revolves around research, development, manufacturing, and distribution of vaccines for various infectious diseases. Valneva aims to partner with pharmaceutical companies, governments, and international organizations to bring safe and effective vaccines to the market, addressing global health challenges.
Sources:
Iovance Biotherapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Iovance Biotherapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
